Targeted Ac-225-radiopharmaceutical for metastatic uveal melanomaPeriod of Performance: 9/18/2017 - 9/17/2019

Information

• Research Project
• 9576556

• ApplicationId

  9576556

• Core Project Number

  N44CA000000

• Full Project Number

  261201700035C-0-0-1

• Serial Number

• FOA Number

• Sub Project Id

• Project Start Date

  9/18/2017 - 7 years ago

• Project End Date

  9/17/2019 - 5 years ago

• Program Officer Name

• Budget Start Date

  -

• Budget End Date

  -

• Fiscal Year

  2017

• Support Year

• Suffix

• Award Notice Date

  -

Organizations

• MODULATION THERAPEUTICS, INC.

Melanocortin 1 receptor (MC1R) is highly expressed on uveal and cutaneous melanoma cells and not on any tissues that are of concern for causing toxicity. We developed a proprietary ligand (MC1RL) that binds to melanoma cells with high affinity and specificity. Our recently completed SBIR Phase I contract results show no overt toxicity at dosages of Ac-225-DOTA-Ahx-MC1RL that produce outstanding efficacy against uveal and cutaneous melanoma in animal models. Biodistribution, radiodosimetry, and PK studies also show rapid blood clearance with predominant distribution to the targeted tumor or to clearance organs with no organ specific pathology. These results are very supportive of possible commercialization of a human drug candidate for the treatment of metastatic melanoma.

IC Name

• Activity

  N44

• Administering IC

  CA

• Application Type

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  1999987

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

• Ed Inst. Type

• Funding ICs

  NCI:1999987\

• Funding Mechanism

  SBIR/STTR Contracts

• Study Section

• Study Section Name

• Organization Name

  MODULATION THERAPEUTICS, INC.

• Organization Department

• Organization DUNS

  968675244

• Organization City

  MORGANTOWN

• Organization State

  WV

• Organization Country

  UNITED STATES

• Organization Zip Code

  26505

• Organization District

  UNITED STATES